San Francisco, CA — December 22, 2025 — Leads & Copy — Natera, Inc. (NASDAQ: NTRA) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026, at 4:30 p.m. PT (7:30 p.m. ET).
Members of management will deliver a presentation and host a Q&A with the investment community at the conference.
A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference.
Natera aims to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance.
Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health.
Source: Natera
